Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Versant Ventures, founded in 1999, is a prominent venture capital firm based in San Diego, California. The firm specializes in biotechnology investments, focusing on creating and nurturing innovative companies that leverage scientific advancements. With $5.3 billion in assets under management (AUM), Versant has built a substantial portfolio of 190 companies, achieving 131 successful exits.
The firm has evolved its approach to venture capital by employing hands-on venture creation strategies. This includes the establishment of multiple Discovery Engines, which are in-house teams of multi-disciplinary scientists that collaborate with academic founders to launch new ventures. Versant's commitment to fostering innovation is evident in its extensive network of over 30 academic partnerships, enhancing its ability to identify and develop breakthrough technologies.
Versant Ventures has made significant strides in the biotech sector, participating in more than 50 initial public offerings (IPOs) and mergers and acquisitions (M&As). The firm operates globally, with a strong emphasis on the United States and Europe, positioning itself as a leader in the biotech investment landscape.
Versant Ventures focuses on the biotechnology sector, investing across various stages from seed to growth equity. The firm targets companies that are founded on scientific discoveries, particularly in the fields of biotech, healthcare, and digital health. Check sizes range from $5 million to $50 million, allowing for flexibility in supporting startups at different stages of development.
The firm employs a hands-on approach to venture creation, utilizing its in-house Discovery Engines to facilitate the launch of new companies. These engines consist of teams of scientists who collaborate closely with academic founders, ensuring that investments are grounded in rigorous scientific research. Versant's geographical focus spans globally, with particular attention to opportunities in the United States and Europe.
Versant Ventures seeks to invest in breakthrough areas of biology, emphasizing the importance of innovation in the life sciences sector. The firm looks for founders who demonstrate a strong scientific background and a clear vision for their companies, valuing deep domain expertise and a commitment to advancing healthcare solutions.
Versant Ventures has built a diverse portfolio of 190 companies, with notable successes in the biotechnology sector. Among its prominent exits are:
Recent portfolio launches include:
Brad Bolzon, Ph.D. - Chairman, Managing Director. Brad has extensive experience in venture capital and biotechnology, having led numerous successful investments in the sector.
Jerel Davis, Ph.D. - Managing Director. Jerel specializes in early-stage biotech investments and has a strong background in scientific research and development.
Alex Mayweg, Ph.D. - Managing Director. Alex focuses on identifying and supporting innovative biotech companies, leveraging his expertise in drug development.
Clare Ozawa, Ph.D. - Managing Director. Clare has a deep understanding of the biotech landscape and has played a key role in several successful exits.
Carlo Rizzuto, Ph.D. - Managing Director. Carlo brings a wealth of experience in operational management and strategic planning within the biotech sector.
Tom Woiwode, Ph.D. - Managing Director. Tom has a strong track record in venture capital and has been instrumental in building successful biotech companies.
Markus Enzelberger, Ph.D. - Partner. Markus focuses on early-stage investments and has a background in scientific research and commercialization.
Nigel Sheail - Partner. Nigel has extensive experience in venture capital and has been involved in numerous successful biotech investments.
Peter Emtage, Ph.D. - Venture Partner. Peter specializes in drug discovery and development, bringing valuable expertise to the firm.
Richard Glynne, Ph.D. - Venture Partner. Richard has a strong background in biotechnology and has led several successful investments.
Kevin Grove, Ph.D. - Venture Partner. Kevin focuses on early-stage biotech investments and has a deep understanding of the industry.
Rami Hannoush, Ph.D. - Venture Partner. Rami specializes in drug development and has a strong track record in the biotech sector.
Tom Hudson, M.D. - Venture Partner. Tom brings clinical expertise to the firm, enhancing its ability to evaluate healthcare investments.
Alicia Levey, Ph.D. - Venture Partner. Alicia focuses on early-stage investments and has a strong background in scientific research.
Zach Sweeney, Ph.D. - Venture Partner. Zach specializes in biotech investments and has a deep understanding of the industry.
Mehmet Badur, Ph.D. - Principal. Mehmet focuses on early-stage biotech investments and has a strong background in scientific research.
Joel Drewry, Ph.D. - Principal. Joel specializes in drug discovery and development, bringing valuable expertise to the firm.
Ariel Kantor, Ph.D. - Principal. Ariel focuses on early-stage investments and has a deep understanding of the biotech landscape.
Nikita Sharma - Principal. Nikita specializes in venture capital and has a strong background in the biotech sector.
Michael Wong, Ph.D. - Principal. Michael focuses on early-stage biotech investments and has a strong background in scientific research.
Laura Quock - CBO-in-Residence. Laura brings extensive experience in business development and commercialization.
Andrew Jefferson - Operating Partner. Andrew focuses on operational support for portfolio companies.
Giorgio Ottaviani, Ph.D. - Operating Partner. Giorgio specializes in scientific research and development.
Rick Dewey, M.D. - Entrepreneur-in-Residence. Rick brings clinical expertise to the firm, enhancing its ability to evaluate healthcare investments.
Ed Olhava, Ph.D. - Scientist-in-Residence. Ed focuses on scientific research and development within the firm.
Startups interested in pitching to Versant Ventures should submit their proposals through the firm's website at versantventures.com. It is important to include a comprehensive deck that outlines the scientific basis of the business, the market opportunity, and the expertise of the founding team.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
Versant Ventures operates multiple Discovery Engines, which are specialized teams that facilitate the creation of new biotechnology companies. These engines are located in various regions, including San Diego and Basel, Switzerland. Each Discovery Engine is designed to support the development of innovative biotech solutions by leveraging in-house scientific expertise and collaboration with academic founders.
On December 1, 2025, Versant Ventures made its latest investment, continuing its active engagement in the biotech sector. Over the past 12 months, the firm has participated in 25 investments, reflecting its commitment to supporting innovative companies.
Versant Ventures has also established over 30 collaborations with academic institutions, enhancing its ability to drive innovation in biotechnology. The firm has participated in more than 50 IPOs and M&As, showcasing its robust engagement in the biotech investment landscape.
What are Versant Ventures' investment criteria?
Versant Ventures invests in biotechnology companies at various stages, from seed to growth equity. The firm focuses on companies founded on scientific discoveries, particularly in biotech, healthcare, and digital health.
How can startups apply or pitch to Versant Ventures?
Startups can pitch to Versant Ventures through their website at versantventures.com. It is recommended to include a detailed deck outlining the scientific basis of the business, market opportunity, and team expertise.
What makes Versant Ventures different from other VC firms?
Versant Ventures distinguishes itself through its hands-on venture creation approach, utilizing in-house Discovery Engines that consist of scientific teams collaborating with academic founders. This model enhances the firm's ability to identify and develop innovative biotech solutions.
What is the geographic scope of Versant Ventures' investments?
Versant Ventures invests globally, with a strong focus on opportunities in the United States and Europe. The firm actively seeks to partner with companies that have the potential to make significant impacts in the biotech sector.
What is the typical check size for investments?
Versant Ventures typically invests between $5 million and $50 million in its portfolio companies, allowing for flexibility in supporting startups at different stages of their development.
What kind of post-investment involvement does Versant Ventures have?
Versant Ventures takes an active role in the companies it invests in, often providing operational support, strategic guidance, and access to its extensive network of academic and industry contacts.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.